Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Oral Health
Published in: BMC Oral Health 1/2018

Open Access 01-12-2018 | Research article

Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis

Authors: Zhen Sun, Wei Gao, Jiang-Tao Cui

Published in: BMC Oral Health | Issue 1/2018

Login to get access

Abstract

Background

There are different and inconsistent conclusions regarding the genetic relationship between the human tumor suppressor p53 (TP53) rs1042522 polymorphism and the risk of oral squamous cell carcinoma (OSCC) and oral leukoplakia (OL). Therefore, the aim of the study was to comprehensively reassess this association through the performance of an updated meta-analysis.

Methods

After searching the available databases, we systematically screened and included the eligible case-control studies, which contain the full genotype frequency data of the TP53 rs1042522 polymorphism for both OSCC/OL patients and the negative control groups. PA (P-value of the association test) and ORs (odd ratios) with their corresponding 95% CIs (confidence intervals) were calculated to quantitatively evaluate the influence of TP53 rs1042522 on the susceptibility of patients to OSCC or OL.

Results

In total, twenty eligible case-control articles were finally enrolled. Compared with the controls, no increased or decreased risk of OSCC was observed in the cases for six genetic models including allele C vs. G (PA = 0.741), carrier C vs. G (PA = 0.853), homozygote CC vs. GG (PA = 0.085), heterozygote GC vs. GG (PA = 0.882), dominant GC + CC vs. GG (PA = 0.969), and recessive CC vs. GG + GC (PA = 0.980). Furthermore, no statistically significant difference between the cases and controls was detected in most subgroup meta-analyses (PA > 0.05). For the risk of OL, we did not observe the difference between the cases and controls for most genetic models in the overall meta-analysis and subsequent subgroup analysis (PA > 0.05). Begg’s test and Egger’s test excluded the large risk of publication bias within the included studies in the meta-analysis of OSCC. The sensitivity analysis indicated the above relatively stable results.

Conclusions

Our updated meta-analysis (based on the current evidence) shows that TP53 rs1042522 may not confer susceptibility to OSCC. In addition, for the first time, we provided evidence regarding the negative association between TP53 rs1042522 and OL risk.
Appendix
Available only for authorised users
Literature
1.
Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320(6057):84–5.CrossRefPubMed
2.
3.
4.
Tian X, Dai S, Sun J, Jiang S, Jiang Y. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: an updated meta-analysis based on 32 studies. Oncotarget. 2017;8(1):1156–65.CrossRefPubMed
5.
Yan Y, Wu R, Li S, He J. Meta-analysis of association between the TP53 Arg72Pro polymorphism and risk of endometriosis based on case-control studies. Eur J Obstet Gynecol Reprod Biol. 2015;189:1–7.CrossRefPubMed
6.
Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, Jorgensen T, et al. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS One. 2011;6(1):e15813.CrossRefPubMedPubMedCentral
7.
Sathiyasekar AC, Chandrasekar P, Pakash A, Kumar KU, Jaishlal MS. Overview of immunology of oral squamous cell carcinoma. J Pharm Bioallied Sci. 2016;8(Suppl 1):S8–s12.PubMedPubMedCentral
8.
Yu CH, Lin HP, Cheng SJ, Sun A, Chen HM. Cryotherapy for oral precancers and cancers. J Formos Med Assoc. 2014;113(5):272–7.CrossRefPubMed
9.
Arduino PG, Bagan J, El-Naggar AK, Carrozzo M. Urban legends series: oral leukoplakia. Oral Dis. 2013;19(7):642–59.CrossRefPubMed
10.
Zarate AM, Don J, Secchi D, Carrica A, Galindez Costa F, Panico R, et al. Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in argentine patients. Tumour Biol. 2017;39(5):1010428317699113.CrossRefPubMed
11.
Lin YC, Huang HI, Wang LH, Tsai CC, Lung O, Dai CY, et al. Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008;44(8):798–804.CrossRefPubMed
12.
Adduri RSR, Katamoni R, Pandilla R, Madana SN, Paripati AK, Kotapalli V, et al. TP53 Pro72 Allele Is Enriched in Oral Tongue Cancer and Frequently Mutated in Esophageal Cancer in India. PLoS One. 2014:9(12).
13.
Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of eastern India. Int J Cancer. 2002;97(5):649–53.CrossRefPubMed
14.
Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, et al. Polymorphism of the p53 codon 72 Arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem. 2003;252(1–2):117–24.CrossRefPubMed
15.
Perrone F, Mariani L, Pastore E, Orsenigo M, Suardi S, Marcomini B, et al. p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer. 2007;109(12):2461–5.CrossRefPubMed
16.
Zhuo XL, Li Q, Zhou Y, Cai L, Xiang ZL, Yuan W, et al. Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res. 2009;40(7):625–34.CrossRefPubMed
17.
Zeng XT, Luo W, Geng PL, Guo Y, Niu YM, Leng WD. Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis. BMC Cancer. 2014;14:469.CrossRefPubMedPubMedCentral
18.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
19.
Kuroda Y, Nakao H, Ikemura K, Katoh T. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol. 2007;43(10):1043–8.CrossRefPubMed
20.
Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008;29(11):2120–5.CrossRefPubMedPubMedCentral
21.
Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183(2):123–30.CrossRefPubMed
22.
Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog. 2009;48(9):790–800.CrossRefPubMed
23.
Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol. 2008;87(2):243–52.CrossRefPubMed
24.
Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, et al. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis. 2008;29(4):875–9.CrossRefPubMed
25.
Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP. p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(3):334–9.CrossRefPubMed
26.
Saini R, Tang TH, Zain RB, Cheong SC, Musa KI, Saini D, et al. Significant association of high-risk human papillomavirus (HPV) but not of p53 polymorphisms with oral squamous cell carcinomas in Malaysia. J Cancer Res Clin Oncol. 2011;137(2):311–20.CrossRefPubMed
27.
Sina M, Pedram M, Ghojazadeh M, Kochaki A, Aghbali A. P53 gene codon 72 polymorphism in patients with oral squamous cell carcinoma in the population of northern Iran. Med Oral Patol Oral Cir Bucal. 2014;19(6):e550–5.CrossRefPubMedPubMedCentral
28.
Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer. 2005;92(1):30–5.CrossRefPubMed
29.
Kietthubthew S, Sriplung H, Au WW, Ishida T. The p53 codon 72 polymorphism and risk of oral cancer in southern Thailand. Asian Pac J Cancer Prev. 2003;4(3):209–14.PubMed
30.
Mitra S, Sikdar N, Misra C, Gupta S, Paul RR, Roy B, et al. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern Idia. Int J Cancer. 2005;117(5):786–93.CrossRefPubMed
31.
Ramya AS, Majumdar S, Babu TM, Uppala D, Srinivas B, Rao AK. Expression of human papillomavirus DNA and p53 polymorphisms through polymerase chain reaction in normal mucosa and oral leukoplakia individuals with deleterious oral habits. Int J Appl Basic Med Res. 2017;7(2):134–8.CrossRefPubMedPubMedCentral
32.
Sikka S, Sikka P. Association of Human Papilloma Virus 16 infection and p53 polymorphism among tobacco using oral leukoplakia patients: a Clinicopathologic and genotypic study. Int J Prev Med. 2014;5(4):430–8.PubMedPubMedCentral
33.
Bau DT, Tsai MH, Lo YL, Hsu CM, Tsai Y, Lee CC, et al. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. Anticancer Res. 2007;27(3b):1559–64.PubMed
34.
Saleem S, Azhar A, Hameed A, Khan MA, Abbasi ZA, Qureshi NR, et al. P53 (Pro72Arg) polymorphism associated with the risk of oral squamous cell carcinoma in gutka, niswar and manpuri addicted patients of Pakistan. Oral Oncol. 2013;49(8):818–23.CrossRefPubMed
35.
36.
Jiang N, Pan J, Wang L, Duan YZ. No significant association between p53 codon 72 Arg/pro polymorphism and risk of oral cancer. Tumour Biol. 2013;34(1):587–96.CrossRefPubMed
37.
Hou J, Gu Y, Hou W, Wu S, Lou Y, Yang W, et al. P53 codon 72 polymorphism, human papillomavirus infection, and their interaction to oral carcinoma susceptibility. BMC Genet. 2015;16:72.CrossRefPubMedPubMedCentral
38.
Drummond SN, De Marco L, Pordeus Ide A, Barbosa AA, Gomez RS. TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res. 2002;22(6a):3379–81.PubMed
39.
Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, et al. Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from north East India. DNA Cell Biol. 2011;30(3):163–71.CrossRefPubMed
40.
Jing G, Lv K, Jiao X. The p53 codon 72 polymorphism and the risk of oral Cancer in a Chinese Han population. Genetic Testing and Molecular Biomarkers. 2012;16(9):1149–52.CrossRefPubMed
41.
Kitkumthorn N, Yanatatsaneejit P, Rabalert J, Dhammawipark C, Mutirangura A. Association of P53 codon 72 polymorphism and ameloblastoma. Oral Dis. 2010;16(7):631–5.CrossRefPubMed
42.
Patel KR, Vajaria BN, Begum R, Shah FD, Patel JB, Shukla SN, et al. Association between p53 gene variants and oral cancer susceptibility in population from Gujarat, West India. Asian Pac J Cancer Prev. 2013;14(2):1093–100.CrossRefPubMed
43.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393(6682):229–34.CrossRefPubMed
44.
Wang Z, Sturgis EM, Zhang Y, Huang Z, Zhou Q, Wei Q, et al. Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 2012;131(3):E251–8.CrossRefPubMed
45.
Zemleduch T, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodzinski PP. Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in polish patients. Oral Oncol. 2009;45(8):683–6.CrossRefPubMed
Metadata
Title
Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis
Authors
Zhen Sun
Wei Gao
Jiang-Tao Cui
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2018
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-018-0603-6

Other articles of this Issue 1/2018

BMC Oral Health 1/2018 Go to the issue

Research article

Barriers to sealant guideline implementation within a multi-site managed care dental practice

Research article

Bactericidal effect of a diode laser on Enterococcus faecalis in human primary teeth—an in vitro study

Research article

Cone beam computed tomography in implant dentistry: recommendations for clinical use

Research article

Dental caries and their association with socioeconomic characteristics, oral hygiene practices and eating habits among preschool children in Abu Dhabi, United Arab Emirates — the NOPLAS project

Research article

Oral health experiences of individuals with Rett syndrome: a retrospective study

Research article

Oral health and health-related quality of life in HIV patients